A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Elderly Male and Female Volunteers During 4 Weeks of Treatment.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2010
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors AstraZeneca
- 23 Jan 2010 Actual number of patients changed from 98 to 97 as reported by ClinicalTrials.gov.
- 23 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.